Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ïåäèàòðèÿ > Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ

Ôîðóì äëÿ îáùåíèÿ âðà÷åé ïåäèàòðîâ Ôîðóì ïðåäíàçíà÷åí òîëüêî äëÿ îáùåíèÿ âðà÷åé ìåæäó ñîáîé. Âîïðîñû ïàöèåíòîâ çàäàþòñÿ íà ôîðóìå Ïåäèàòðèÿ.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #151  
Ñòàðûé 06.10.2015, 17:58
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,421 ðàç(à) çà 31,766 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ðàáîòà èç Êàíàäû î ïðåäàíåìè÷åñêîì äåôèöèòå æåëåçà ó äåòåé: ÷àñòîòà, ôàêòîðû ðèñêà, êàê ÷àñòî êîððåêòèðóåòñÿ âðà÷àìè è êàêîâ ðåçóëüòàò:

Of 2276 children undergoing screening, 155 had Of 2276 children undergoing screening, 155 had non-anemic iron deficiency (NAID), corresponding to a prevalence of 7% (95% CI 5.95% to 8.05%). Risk factors significantly associated with NAID included: younger age (OR 1.08 [95% CI 1.06 to 1.11]), higher body mass index z-score (OR 1.22 [95% CI 1.01 to 1.48]), longer duration of breastfeeding (OR 1.05 [95% CI 1.01 to 1.08]) and increased volume of cow's milk intake (OR 1.13 [95% CI 1.01 to 1.26]). An assessment of practice patterns revealed that for 37% of children, an intervention for NAID was documented; and for 8.4% a physician-ordered follow-up laboratory test was completed to re-evaluate iron status. A total of 58 (37%) children underwent a follow-up laboratory test, of whom 38 (65.5%) had resolution of NAID, 15 (25.9%) had persistence of NAID and two (3.4%) had progression of NAID to anemia.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #152  
Ñòàðûé 07.10.2015, 01:01
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äîêëàä AAP ïî ìëàäåí÷åñêèì ãåìàíãèîìàì

Îïóáëèêîâàí äîêëàä Àìåðèêàíñêîé àêàäåìèè ïåäèàòðèè ïî ìëàäåí÷åñêèì ãåìàíãèîìàì. Ïåðâûé â ñâîåì ðîäå. Ýòî íå ãàéäëàéí, ýòî ÷èñòî îáó÷àþùåå ðóêîâîäñòâî, ñóììèðóþùåå ïîñëåäíèå íàó÷íûå äàííûå ïî ýòîé ïðîáëåìå.

Äîêëàä êðàñî÷íî è îáèëüíî èëëþñòðèðîâàí ôîòîãðàôèÿìè. Ïðèãîäèòñÿ êàê ïåäèàòðàì, òàê è âðà÷àì äðóãèõ ñïåöèàëüíîñòåé, èìåþùèì äåëî ñ ìëàäåí÷åñêèìè ãåìàíãèîìàìè.

Íîâîñòü: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ïîëíîòåêñò: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
ggg650 îäîáðèë(à): Ñïàñèáî!
Âëîæåíèÿ
Òèï ôàéëà: pdf Pediatrics-2015-Darrow-peds.2015-2485.pdf (2.85 Ìá, 460 ïðîñìîòðîâ)
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #153  
Ñòàðûé 22.10.2015, 17:14
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,421 ðàç(à) çà 31,766 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Èçáûòîê êîðîâüåãî ìîëîêà â ðàöèîíå äåòåé 1-3 ëåò èç Åâðîïû àññîöèèðóåòñÿ ñ ðèñêîì êàê äåôèöèòà æåëåçà, òàê è äåôèöèòîì âèòàìèíà Ä, êîè âñòðå÷àþòñÿ â ýòîì âîçðàñòå ñ ÷àñòîòîé 12% è 23% ñîîòâåòñòâåííî:

In 325 children (Caucasian race 95%; male 56%; mean age 20.7 months) the overall prevalence of ID and VDD was 11.8% and 22.8%, respectively. The use of primarily cow's milk as major type of milk was associated with ID (OR 3.20, 95% CI 1.12-8.53) and VDD (OR 7.17, 95% CI 3.10-16.57). The use of vitamin D supplements (OR 0.20, 95% CI 0.07-0.56) was associated with a lower prevalence of VDD.

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #154  
Ñòàðûé 18.11.2015, 10:57
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íó âîò
ÐÌÑ ìåíÿ íàó÷èë ôîðìóëå "íà ãðóäíîì âñêàðìëèâàíèè íå áûâàåò îæèðåíèÿ", è ÿ ÷àñòî óñïîêàèâàë ýòèì ìàòåðåé. Îäíàêî íîâîå èññëåäîâàíèå îïðîâåðãàåò ýòó òî÷êó çðåíèÿ.

Öèòàòà:
The aim of the study is to examine the association of feeding type (exclusive breast feeding (EBF), formula feeding or mixed feeding) and overweight at the age of 6 months with the risk of overweight at the age of 5–6 years.
Öèòàòà:
Öåëüþ ýòîé íàó÷íîé ðàáîòû ÿâëÿëîñü èçó÷åíèå âëèÿíèÿ âèäà âñêàðìëèâàíèÿ (èñêëþ÷èòåëüíî ãðóäíîå ìîëîêî, èñêóññòâåííîå âñêàðìëèâàíèå èëè ñìåøàííîå âñêàðìëèâàíèå), ó ìëàäåíöåâ â âîçðàñòå 6 ìåñÿöåâ ñ èçáûòî÷íûì âåñîì, íà ðèñê ðàçâèòèÿ èçáûòî÷íîãî âåñà â âîçðàñòå 5-6 ëåò.
Êîëè÷åñòâî ó÷àñòíèêîâ 3367 ÷åëîâåê. Èññëåäîâàíèå ïðîñïåêòèâíîå, ïîïóëÿöèîííîå, êîãîðòíîå.

Öèòàòà:
Conclusions Overweight in infancy increases the odds of childhood overweight, equally for exclusively breastfed and formula fed infants. Overweight prevention should start before or at birth and applies to formula fed children as well as exclusively breastfed children.
Öèòàòà:
Âûâîäû: èçáûòî÷íûé âåñ â ìëàäåí÷åñòâå óâåëè÷èâàåò ðèñê èçáûòî÷íîãî âåñà â äîøêîëüíîì âîçðàñòå, âíå çàâèñèìîñòè îò òèïà âñêàðìëèâàíèÿ. Ïðîôèëàêòèêà èçáûòî÷íîãî âåñà äîëæíà íà÷èíàòüñÿ äî èëè ñðàçó ïîñëå ðîæäåíèÿ, è â ðàâíîé ñòåïåíè àêòóàëüíà êàê äëÿ ìëàäåíöåâ íà èñêóññòâåííûõ ñìåñÿõ, òàê è äëÿ ìëàäåíöåâ íà ïîëíîì ãðóäíîì âñêàðìëèâàíèè.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
SergMak îäîáðèë(à):
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #155  
Ñòàðûé 18.11.2015, 12:15
SergMak SergMak âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 04.12.2011
Ãîðîä: Âèííèöà
Ñîîáùåíèé: 305
Ñêàçàë(à) ñïàñèáî: 28
Ïîáëàãîäàðèëè 138 ðàç(à) çà 104 ñîîáùåíèé
SergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À â ÷åì òîãäà çàêëþ÷àåòñÿ ïðîôèëàêòèêà îæèðåíèÿ íà ÃÂ?
Êîðìèòü ïî ÷àñàì? Ïîèòü âîäîé âìåñòî ìîëîêà? Ðàçáàâëÿòü ìîëîêî?

Êîììåíòàðèè ê ñîîáùåíèþ:
SergDoc îäîáðèë(à): Íå äåòàëèçèðóåòñÿ. Ó ìåíÿ òîæå âîçíèêëè ýòè âîïðîñû Íàäî ïî÷èòàòü
Loran1955 îäîáðèë(à): Ó âñåõ ýòè âîïðîñû )))
Îòâåòèòü ñ öèòèðîâàíèåì
  #156  
Ñòàðûé 21.11.2015, 18:36
Àâàòàð äëÿ BarbaraZh
BarbaraZh BarbaraZh âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 01.02.2011
Ãîðîä: Kabul-Dushanbe
Ñîîáùåíèé: 296
Ñêàçàë(à) ñïàñèáî: 60
Ïîáëàãîäàðèëè 102 ðàç(à) çà 72 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 7
BarbaraZh ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBarbaraZh ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBarbaraZh ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBarbaraZh ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äûê òî ïîäè ó àìåðèêàíñêèõ ëþäåé òàêèå ïðîáëåìû - îíè óæå ïîìåøàëèñü íà îæèðåíèè è åãî ïðîôèëàêòèêå

Exclusive breastfeeding to reduce the risk of childhood overweight and obesity

Biological, behavioural and contextual rationale

WHO technical staff
September 2014
Îòâåòèòü ñ öèòèðîâàíèåì
  #157  
Ñòàðûé 27.11.2015, 17:59
SergMak SergMak âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 04.12.2011
Ãîðîä: Âèííèöà
Ñîîáùåíèé: 305
Ñêàçàë(à) ñïàñèáî: 28
Ïîáëàãîäàðèëè 138 ðàç(à) çà 104 ñîîáùåíèé
SergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergMak ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò SergDoc Ïîñìîòðåòü ñîîáùåíèå
Íó âîò
ÐÌÑ ìåíÿ íàó÷èë ôîðìóëå "íà ãðóäíîì âñêàðìëèâàíèè íå áûâàåò îæèðåíèÿ", è ÿ ÷àñòî óñïîêàèâàë ýòèì ìàòåðåé. Îäíàêî íîâîå èññëåäîâàíèå îïðîâåðãàåò ýòó òî÷êó çðåíèÿ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Ìíå äîëãî íå äàâàëà ïîêîÿ ìûñëü, ÷òî â âûâîäàõ ýòîãî èññëåäîâàíèÿ ÷òî-òî íå ó÷òåíî. À ïîòîì ïîíÿë - íå ïðèíèìàëè âî âíèìàíèå âåñ ðîäèòåëåé. Èç ìîèõ íàáëþäåíèé - êðóïíûå ãðóäíè÷êè, ïðåèìóùåñòâåííî (íî íå âñåãäà) ó êðóïíûõ ðîäèòåëåé. Çíà÷èò, ìëàäåíöû ñ èçáûòêîì âåñà âûðàñòàþò â ïóõëûõ òîäëåðîâ è ïðåñêóëåðîâ íå ïîòîìó, ÷òî ïåðååäàëè ãðóäíîãî ìîëîêà, à ïðîñòî êîíñòèòóöèÿ òàêàÿ, óíàñëåäîâàííàÿ îò ðîäèòåëåé?

ß äî ñèõ ïîð óìà íå ïðèëîæó, êàê ýòî ïðîôèëàêòèðîâàòü îæèðåíèå íà ÃÂ (ýòèì âîïðîñîì çàäàâàëñÿ âûøå). Ìîðèòü ãîëîäîì, ÷òîáû îáìàíóòü ãåíû?

Õîòÿ ÿ ïðåêðàñíî ïîíèìàþ, ÷òî ñåìåéíîå îæèðåíèå - ýòî çà÷àñòóþ íå óíàñëåäîâàííûé îáìåí âåùåñòâ, à óíàñëåäîâàííûå ïèùåâûå ïðèâû÷êè. Íî âñå æå...
Îòâåòèòü ñ öèòèðîâàíèåì
  #158  
Ñòàðûé 08.01.2016, 12:29
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Î âàêöèíå Âèòàãåðïàâàê äëÿ äåòåé

Ðûëñÿ ïî òåðàïèè óïîðíîãî ðåöèäèâèðóþùåãî ãóáíîãî ãåðïåñà ó òðåõëåòêè, è íàøåë ïðî ëå÷åáíûå âàêöèíû èíôó.
Äåëþñü

Öèòàòà:
Therapeutic vaccines

An alternative strategy to augment immune responses and suppress or modulate HSV recurrences is the development of a therapeutic vaccine. Although no randomized clinical trial to date has demonstrated a clear therapeutic benefit, they have provided important insights for future studies. A reduction in recurrences was suggested in response to the Lupidon H and Lupidon G vaccines, which are comprised of whole heat-killed virus from HSV-1 and HSV-2, respectively, although the results were inconclusive due to a lack of appropriate controls and the number of other interventions during the study [48]. A reduction in the number and severity of recurrences was also suggested following immunization with the Skinner vaccine, an inactivated subunit vaccine containing mixed HSV-2 glyco proteins; however, the results were not statistically significant [49]. A disabled infectious single-cycle viral vaccine carrying a deletion of glycoprotein H demonstrated initial promise in animal models [50], but failed to demonstrate protection against recurrences in a Phase II trial [51]. The recombinant glycoprotein vaccine developed by Chriron (MA, USA), gD2gB2-MF59, also did not reduce rates of recurrences or viral shedding, but did reduce symptom and lesion duration [52]. Promising results were more recently obtained in Phase I/II clinical trials with a live-attenuated ICP0 deletion virus, ICP10DPK, which completely prevented recurrences in 37.5 and 43.5% of the vaccinated patients in two trials [53]. Further development and identification of therapeutic vaccine candidates are needed, but mathematical modeling supports the development of a therapeutic HSV vaccine, which could provide both a therapeutic and epidemic-level benefit [54].
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîãäà ñïåöèàëüíî èñêàë ïî çàïðîñó íà âàêöèíû - íå ìîã íàéò

Ñîáñòâåííî íè÷åãî íîâîãî íå óçíàë - äîêàçàòåëüíàÿ áàçà ñëàáàÿ, íî ìîæíî ïîïðîáîâàòü îò îò÷àÿíèÿ èíîãäà. Òàê ìàìå è ñêàçàë.
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #159  
Ñòàðûé 20.01.2016, 10:15
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñòàòüÿ î òîì êàê íå ñïóòàòü child abuse ñ èñòèííûìè êîæíûìè áîëåçíÿìè, êîãäà ïîñëåäíèå î÷åíü ïîõîæè íà ñëåäû íàñèëèÿ
Îñòîðîæíî, ñòàòüÿ ñòðîãî äëÿ âðà÷åé, ôîòîãðàôèè íå äëÿ ñëàáîíåðâíûõ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #160  
Ñòàðûé 05.02.2016, 11:42
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Àðáèäîë ñòàë ïëîõî ïðîäàâàòüñÿ, ÷òî ëè. Íà÷àëèñü àãðåññèâíûå ïèàð-êàìïàíèè â ñîöñåòÿõ è ïðîôåññèîíàëüíûõ ìåäèöèíñêèõ ôîðóìàõ. Àâòîðû ñûïÿò ññûëêàìè íà èññëåäîâàíèÿ óìèôåíîâèðà â Ïàáìåäå è íåèñêóøåííûé äîêòîð âïîëíå ìîæåò ðàñòåðÿòüñÿ è çàïóòàòüñÿ (íàïðèìåð, ìåíÿ îñåíüþ ìåäïðåä ñìóòèëà â äèñêóññèè, ÿ íå äîâåðÿþ àðáèäîëó, íî íå çíàë ÷åì åé îïïîíèðîâàòü).

Ñîâåòóþ êîëëåãàì ïðî÷åñòü ýòî âðà÷åáíîå îáñóæäåíèå, ÷òîáû áûòü çíàêîìûì ñ àðãóìåíòàìè îáåèõ ñòîðîí

[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
Elena_Melnik îäîáðèë(à):
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #161  
Ñòàðûé 26.02.2016, 16:05
Àâàòàð äëÿ OlgaGenze
OlgaGenze OlgaGenze âíå ôîðóìà ÂÐÀ×
Êàíäèäàò â âåòåðàíû ôîðóìà
      
 
Ðåãèñòðàöèÿ: 29.03.2012
Ãîðîä: Òîìñê
Ñîîáùåíèé: 1,353
Ñêàçàë(à) ñïàñèáî: 17
Ïîáëàãîäàðèëè 671 ðàç(à) çà 627 ñîîáùåíèé
OlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåOlgaGenze ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñõåìàòè÷íûé êðàòêèé ãàéä ïî êðóïó, ìíå ïîíðàâèëñÿ: [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ].

Êîììåíòàðèè ê ñîîáùåíèþ:
SergDoc îäîáðèë(à):
eduardshraibman îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #162  
Ñòàðûé 01.07.2016, 11:49
Àâàòàð äëÿ eduardshraibman
eduardshraibman eduardshraibman âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.10.2010
Ãîðîä: hadera
Ñîîáùåíèé: 17,944
Ñêàçàë(à) ñïàñèáî: 15
Ïîáëàãîäàðèëè 9,362 ðàç(à) çà 8,936 ñîîáùåíèé
eduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåeduardshraibman ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
íåîíàòàëüíûé ãåìàíãèîìàòîç
Õîòÿ âñòðå÷àåòñÿ íå ÷àñòî, íî 1-3 ðàçà â ïðàêòèêå âðà÷à ìîæåò âñòðåòèòñÿ. Ðåêîìåíäóþ ñòàòüþ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Neonatal Hemangiomatosis
Ãåìàíãèîìàòîç, îïðåäåëÿåòñÿ êàê êðàòíîå (êàê ïðàâèëî, ïÿòü èëè áîëåå) ãåìàíãèîì, ïðåäñòàâëåí íåáîëüøèìè êîæíûìè ãåìàíãèîìàìè(êðàñíûå ïàïóëû è óçåëêè âàðüèðóþòñÿ â ðàçìåðàõ îò áóëàâî÷íîé ãîëîâêè äî 1 ñì), êîòîðûå ìîãóò âîçíèêíóòü â ëþáîì ìåñòå íà êîæå èëè ñëèçèñòûõ îáîëî÷åê.  äîïîëíåíèå ê êîæíûìè ïîðàæåíèÿìè, hemangiomatosis ìîæåò âêëþ÷àòü âíóòðåííèå îðãàíû, â òîì ÷èñëå, íî íå îãðàíè÷èâàÿñü èìè, ïå÷åíü, æåëóäî÷íî-êèøå÷í.òðàêò è ãîëîâíîé ìîçã.

ïðèìèòèâíûé ïåðåáîä äëÿ ëåíèâûõ çäåñü http://forums.rusmedserv.com/showthr...11#post2416911

Êîììåíòàðèè ê ñîîáùåíèþ:
ggg650 îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #163  
Ñòàðûé 09.02.2017, 01:04
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,421 ðàç(à) çà 31,766 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Êàê è ïî÷åìó ãîìåîïàòèÿ ìîæåò ïðîâîäèòü ê âîçíèêíîâåíèþ ïîá. ýôôåêòîâ è äàæå ñìåðòè ìàëåíüêèõ äåòåé - â ïîñëåäíåì íîìåðå æóðíàëà
Amid Reports of Infant Deaths, FTC Cracks Down on Homeopathy While FDA Investigates
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
SergDoc îäîáðèë(à):
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #164  
Ñòàðûé 22.02.2017, 22:52
Àâàòàð äëÿ SergDoc
SergDoc SergDoc âíå ôîðóìà
Ïðîâèíöèàëüíûé ïåäèàòð
      
 
Ðåãèñòðàöèÿ: 05.02.2009
Ãîðîä: Èâàíîâî; ÐÔ
Ñîîáùåíèé: 11,385
Ñêàçàë(à) ñïàñèáî: 27
Ïîáëàãîäàðèëè 8,230 ðàç(à) çà 4,753 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 44
SergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSergDoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Âèäåîïðåçåíòàöèÿ Áóòðèÿ ÑÀ î òàêòèêå ïðîâåäåíèÿ äîãîíÿþùåé âàêöèíàöèè ó äåòåé

Âîçìîæíî êîëëåãàì áóäåò èíòåðåñíà ìîÿ âèäåîïðåçåíòàöèÿ
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Òîëüêî ïîìíèòå: ôîðóì - íå çàìåíà î÷íîìó âðà÷ó, à ëå÷åíèå ïî èíòåðíåòó - ÷ðåâàòî ñìåðòüþ îò îïå÷àòêè.
Ñ óâàæåíèåì, Ñåðãåé Àëåêñàíäðîâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
  #165  
Ñòàðûé 15.06.2017, 22:00
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad âíå ôîðóìà
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,786
Ïîáëàãîäàðèëè 33,421 ðàç(à) çà 31,766 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äâå íåäàâíèå ïóáëèêàöèè èç Èçðàèëÿ î ïîâûøåííîì ðèñêå îïóõîëåé ó äåòåé, çà÷àòûõ ïðè èñïîëüçîâàíèè âñïîìîãàòåëüíûõ òåõíîëîãèé (ÝÊÎ è òï.):

Pediatr Blood Cancer. 2017 Apr;64(4).
Possible risk for cancer among children born following assisted reproductive technology in Israel.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Am J Obstet Gynecol. 2017 Mar;216(3):314.e1-314.e14.
Fertility treatments and pediatric neoplasms of the offspring: results of a population-based cohort with a median follow-up of 10 years.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Êîììåíòàðèè ê ñîîáùåíèþ:
eduardshraibman îäîáðèë(à):
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 19:23.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.